antidiabetic

• adj.

• 抗糖尿病の、抗糖尿病性の

• n.

• 抗糖尿病薬、抗糖尿病剤

関

antidiabetic agent、antidiabetic drug、antidiabetics

　

WordNet

1. a drug used to treat diabetes mellitus (同)antidiabetic_drug

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/23 20:48:38」(JST)

wiki en

[Wiki en表示]

Drugs used in diabetes treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.

Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type I, which must be injected.

Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.

Several groups of drugs, mostly given by mouth, are effective in Type II, often in combination. The therapeutic combination in Type II may include insulin, not necessarily because oral agents have failed completely, but in search of a desired combination of effects. The great advantage of injected insulin in Type II is that a well-educated patient can adjust the dose, or even take additional doses, when blood glucose levels measured by the patient, usually with a simple meter, as needed by the measured amount of sugar in the blood.

Insulin

Main article: insulin (medication)

Insulin is usually given subcutaneously, either by injections or by an insulin pump. Research of other routes of administration is underway. In acute-care settings, insulin may also be given intravenously. In general, there are three types of insulin, characterized by the rate which they are metabolized by the body. They are rapid acting insulins, intermediate acting insulins and long acting insulins.

Examples of rapid acting insulins include

• Regular insulin (Humulin R, Novolin R)
• Insulin lispro (Humalog)
• Insulin aspart (Novolog)
• Insulin glulisine (Apidra)
• Prompt insulin zinc (Semilente, Slightly slower acting)

Examples of intermediate acting insulins include

• Isophane insulin, neutral protamine Hagedorn (NPH) (Humulin N, Novolin N)
• Insulin zinc (Lente)

Examples of long acting insulins include

• Extended insulin zinc insulin (Ultralente)
• Insulin glargine (Lantus)
• Insulin detemir (Levemir)

Comparison

The following table compares some common anti-diabetic agents, generalizing classes, although there may be substantial variation in individual drugs of each class. When the table makes a comparison such as "lower risk" or "more convenient" the comparison is with the other drugs on the table.

Comparison of anti-diabetic medication
agent	mechanism	advantages	disadvantages
Sulfonylurea (glyburide, glimepiride, glipizide)	Stimulating insulin release by pancreatic beta cells by inhibiting the KATP channel	Inexpensive Fast onset of action No effect on blood pressure No effect on low-density lipoprotein lower risk of gastrointestinal problems than with metformin more convenient dosing	causes an average of 5–10 pounds weight gain Increased risk of hypoglycemia Glyburide has increases risk of hypoglycemia slightly more as compared with glimepiride and glipizide Higher risk of death compared with metformin
Metformin	Acts on the liver to reduce gluconeogenesis and causes a decrease in insulin resistance via increasing AMPK signalling.	Not associated with weight gain Low risk of hypoglycemia as compared to alternatives Good effect on LDL cholesterol Decreases triglycerides No effect on blood pressure Inexpensive	increased risk of gastrointestinal problems Contraindicated for people with moderate or severe kidney disease or heart failure because of risk of lactic acidosis due to Alcoholism increased risk of Vitamin B12 deficiency less convenient dosing Metallic taste
Alpha-glucosidase inhibitor (acarbose, miglitol, voglibose)	Reduces glucose absorbance by acting on small intestine to cause decrease in production of enzymes needed to digest carbohydrates	slightly decreased risk of hypoglycemia as compared to sulfonylurea not associated with weight gain decreases triglycerides no effect on cholesterol	less effective than most other diabetes pills in decreasing glycated hemoglobin increased risk of GI problems than other diabetes pills except metformin inconvenient dosing expensive
Thiazolidinediones (Pioglitazone, Rosiglitazone)	Reduce insulin resistance by activating PPAR-γ in fat and muscle	Lower risk of hypoglycemia Slight increase in high-density lipoprotein Actos linked to decreased triglycerides Convenient dosing	increased risk of heart failure causes an average of 5–10 pounds weight gain associated with higher risk of edema associated with higher risk of anemia increases low-density lipoprotein Avandia linked to increased triglycerides and risk of heart attack Actos linked to increased risk of bladder cancer slower onset of action requires monitoring for hepatoxicity associated with increased risk of limb fractures expensive

Most anti-diabetic agents are contraindicated in pregnancy, in which insulin is preferred.

Sensitizers

Insulin sensitizers address the core problem in Type II diabetes—insulin resistance.

Biguanides

Main article: Biguanide

Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, including skeletal muscle. Although it must be used with caution in patients with impaired liver or kidney function, metformin, a biguanide, has become the most commonly used agent for type 2 diabetes in children and teenagers. Among common diabetic drugs, metformin is the only widely used oral drug that does not cause weight gain.

Typical reduction in glycated hemoglobin (A1C) values for metformin is 1.5–2.0%

• Metformin (Glucophage) may be the best choice for patients who also have heart failure, but it should be temporarily discontinued before any radiographic procedure involving intravenous iodinated contrast, as patients are at an increased risk of lactic acidosis.
• Phenformin (DBI) was used from 1960s through 1980s, but was withdrawn due to lactic acidosis risk.
• Buformin also was withdrawn due to lactic acidosis risk.

Metformin is usually the first-line medication used for treatment of type 2 diabetes. In general, it is prescribed at initial diagnosis in conjunction with exercise and weight loss, as opposed to in the past, where it was prescribed after diet and exercise had failed. There is an immediate release as well as an extended-release formulation, typically reserved for patients experiencing GI side-effects. It is also available in combination with other oral diabetic medications.

Thiazolidinediones

Main article: Thiazolidinedione

Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism. These PPARs act on peroxysome proliferator responsive elements (PPRE). The PPREs influence insulin-sensitive genes, which enhance production of mRNAs of insulin-dependent enzymes. The final result is better use of glucose by the cells.

Typical reductions in glycated hemoglobin (A1C) values are 1.5–2.0%. Some examples are:

• rosiglitazone (Avandia): the European Medicines Agency recommended in September 2010 that it be suspended from the EU market due to elevated cardiovascular risks.
• pioglitazone (Actos)
• troglitazone (Rezulin): used in 1990s, withdrawn due to hepatitis and liver damage risk

Multiple retrospective studies have resulted in a concern about rosiglitazone's safety, although it is established that the group, as a whole, has beneficial effects on diabetes. The greatest concern is an increase in the number of severe cardiac events in patients taking it. The ADOPT study showed that initial therapy with drugs of this type may prevent the progression of disease, as did the DREAM trial.

Concerns about the safety of rosiglitazone arose when a retrospective meta-analysis was published in the New England Journal of Medicine. There have been a significant number of publications since then, and a Food and Drug Administration panel voted, with some controversy, 20:3 that available studies "supported a signal of harm," but voted 22:1 to keep the drug on the market. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate the issue, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control. Safety studies are continuing.

In contrast, at least one large prospective study, PROactive 05, has shown that pioglitazone may decrease the overall incidence of cardiac events in people with type 2 diabetes who have already had a heart attack.

Secretagogues

Secretagogues are drugs that increase insulin output from the pancreas.

Sulfonylureas

Main article: Sulfonylurea

Sulfonylureas were the first widely used oral anti-hyperglycaemic medications. They are insulin secretagogues, triggering insulin release by inhibiting the K_ATP channel of the pancreatic beta cells. Eight types of these pills have been marketed in North America, but not all remain available. The "second-generation" drugs are now more commonly used. They are more effective than first-generation drugs and have fewer side-effects. All may cause weight gain.

Sulfonylureas bind strongly to plasma proteins. Sulfonylureas are useful only in Type II diabetes, as they work by stimulating endogenous release of insulin. They work best with patients over 40 years old who have had diabetes mellitus for under ten years. They cannot be used with type I diabetes, or diabetes of pregnancy. They can be safely used with metformin or -glitazones. The primary side-effect is hypoglycemia.

Typical reductions in glycated hemoglobin (A1C) values for second-generation sulfonylureas are 1.0–2.0%.

• First-generation agents
  • tolbutamide (Orinase, Rastinon brand name )
  • acetohexamide (Dymelor)
  • tolazamide (Tolinase)
  • chlorpropamide (Diabinese)
• Second-generation agents
  • glipizide (Glucotrol, Minidiab, Glibenese)
  • glyburide or glibenclamide (Diabeta, Micronase, Glynase, Daonil, Euglycon)
  • glimepiride (Amaryl)
  • gliclazide (Uni Diamicron)
  • glycopyramide
  • gliquidone (Glurenorm)

Nonsulfonylurea secretagogues

Meglitinides

Main article: Meglitinide

Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues." They act on the same potassium channels as sulfonylureas, but at a different binding site. By closing the potassium channels of the pancreatic beta cells, they open the calcium channels, thereby enhancing insulin secretion.

They are taken with or shortly before meals to boost the insulin response to each meal. If a meal is skipped, the medication is also skipped.

Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.

• repaglinide (Prandin, NovoNorm)
• nateglinide (Starlix)

Adverse reactions include weight gain and hypoglycemia.

Alpha-glucosidase inhibitors

Main article: Alpha-glucosidase inhibitor

Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, so that glucose from the starch of a meal enters the bloodstream more slowly, and can be matched more effectively by an impaired insulin response or sensitivity. These agents are effective by themselves only in the earliest stages of impaired glucose tolerance, but can be helpful in combination with other agents in type 2 diabetes.

Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.

• miglitol (Glyset)
• acarbose (Precose/Glucobay)
• voglibose

These medications are rarely used in the United States because of the severity of their side-effects (flatulence and bloating). They are more commonly prescribed in Europe. They do have the potential to cause weight loss by lowering the amount of sugar metabolized.

Peptide analogs

Overview of insulin secretion

Injectable Incretin mimetics

Incretins are insulin secretagogues. The two main candidate molecules that fulfill criteria for being an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (glucose-dependent insulinotropic peptide, GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

Injectable Glucagon-like peptide analogs and agonists

Glucagon-like peptide (GLP) agonists bind to a membrane GLP receptor. As a consequence, insulin release from the pancreatic beta cells is increased. Endogenous GLP has a half-life of only a few minutes, thus an analogue of GLP would not be practical.

• Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP but rather a GLP agonist. Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life. Typical reductions in A1C values are 0.5–1.0%.
• Liraglutide, a once-daily human analogue (97% homology), has been developed by Novo Nordisk under the brand name Victoza. The product was approved by the European Medicines Agency (EMEA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.
• Taspoglutide is presently in Phase III clinical trials with Hoffman-La Roche.
• Lixisenatide (Lyxumia) Sanofi Aventis

These agents may also cause a decrease in gastric motility, responsible for the common side-effect of nausea, and is probably the mechanism by which weight loss occurs.

Gastric inhibitory peptide analogs

• None are FDA approved

Dipeptidyl Peptidase-4 Inhibitors

Main article: Dipeptidyl peptidase-4 inhibitors

GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general DPP-4 inhibitors were weight-neutral and increased risk for infection and headache, but both classes appear to present an alternative to other antidiabetic drugs. However, weight gain and/or hypoglycaemia have been observed when DPP-4 inhibitors were used with sulfonylureas; effect on long-term health and morbidity rates are still unknown.

Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4.

Examples are:

• vildagliptin (Galvus) EU Approved 2008
• sitagliptin (Januvia) FDA approved Oct 2006
• saxagliptin (Onglyza) FDA Approved July 2009
• linagliptin (Tradjenta) FDA Approved May 2, 2011
• alogliptin
• septagliptin

DPP-4 inhibitors lowered hemoglobin A1C values by 0.74%, comparable to other antidiabetic drugs.

A result in one RCT comprising 206 patients aged 65 or older (mean baseline HgbA1c of 7.8%) receiving either 50 or 100 mg/d of Sitagliptin was shown to reduce HbA1c by 0.7% (combined result of both doses). A combined result of 5 RCTs enlisting a total of 279 patients aged 65 or older (mean baseline HbA1c of 8%) receiving 5 mg/d of Saxagliptin was shown to reduce HbA1c by 0.73%. A combined result of 5 RCTs enlisting a total of 238 patients aged 65 or older (mean baseline HbA1c of 8.6%) receiving 100 mg/d of Vildagliptin was shown to reduce HbA1c by 1.2%. Another set of 6 combined RCTs involving Alogliptin (not yet approved, might be released in 2012) was shown to reduce HbA1c by 0.73% in 455 patients aged 65 or older who received 12.5 or 25 mg/d of the medication.

Injectable Amylin analogues

Amylin agonist analogues slow gastric emptying and suppress glucagon. They have all the incretins actions except stimulation of insulin secretion. As of 2007, pramlintide is the only clinically available amylin analogue. Like insulin, it is administered by subcutaneous injection. The most frequent and severe adverse effect of pramlintide is nausea, which occurs mostly at the beginning of treatment and gradually reduces. Typical reductions in A1C values are 0.5–1.0%.

Glycosurics

SGLT-2 inhibitors block the re-uptake of glucose in the renal tubules, promoting loss of glucose in the urine. This causes both mild weight loss, and a mild reduction in blood sugar levels with little risk of hypoglycaemia. Urinary tract infection is a common side effect. Examples of SGLT-2 inhibitors include:

• Canagliflozin (Invokana - FDA approved March 2013)
• Dapagliflozin (marketed in Europe as Forxiga)

Natural substances

Plants

A number of medicinal plants have been studied for the treatment of diabetes, however there is insufficient evidence to determine their effectiveness. Cinnamon has blood sugar-lowering properties, however whether or not it is useful for treating diabetes is unknown. Researchers from Australia's Swinburne University have found extracts from Australian Sandalwood and Indian Kino tree slows down two key enzymes in carbohydrate metabolism. Bioassay-directed fractionation techniques led to isolation of isoorientin as the main hypoglycemic component in Gentiana olivieri.

Elements

While chromium supplements have no beneficial effect on healthy people, there might be an improvement in glucose metabolism in individuals with diabetes, although the evidence for this effect remains weak. Vanadyl sulfate, a salt of vanadium, is still in preliminary studies. There is tentative research that thiamine may prevent some diabetic complications however more research is needed.

Generic

Many anti-diabetes drugs are available as generics. These include:

• Sulfonylureas - glimepiride, glipizide, glyburide
• Biguanides - metformin
• Thiazolidinediones (Tzd) - pioglitazone, Actos generic
• Alpha-glucosidase inhibitors - Acarbose
• Meglitinides - nateglinide
• Combination of sulfonylureas plus metformin - known by generic names of the two drugs

No generics are available for dipeptidyl peptidase-4 inhibitors (Januvia, Onglyza) and other combinations.

References

Further reading

• Lebovitz, Harold E. (2004). Therapy For Diabetes Mellitus and Related Disorders (4th ed.). Alexandria, VA: American Diabetes Association. ISBN 1-58040-187-2. 
• Adams, Michael Ian; Holland, Norman Norwood (2003). Core Concepts in Pharmacology. Englewood Cliffs, NJ: Prentice Hall. ISBN 0-13-089329-3. 

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 2型糖尿病の治療のためのジペプチジルペプチダーゼ4（DPP-4）阻害剤 dipeptidyl peptidase 4 dpp 4 inhibitors for the treatment of type 2 diabetes mellitus
• 2. 2型糖尿病治療のためのGlucagon-like peptide-1受容体拮抗剤 glucagon like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus
• 3. 糖尿病における吸入インスリン療法 inhaled insulin therapy in diabetes mellitus
• 4. メトホルミン中毒 metformin poisoning
• 5. 糖尿病を有する成人における血糖の周術期マネージメント perioperative management of blood glucose in adults with diabetes mellitus

English Journal

• Effect of stevia and citric acid on the stability of phenolic compounds and in vitro antioxidant and antidiabetic capacity of a roselle (Hibiscus sabdariffa L.) beverage.

• Pérez-Ramírez IF1, Castaño-Tostado E1, Ramírez-de León JA2, Rocha-Guzmán NE3, Reynoso-Camacho R4.
• Food chemistry.Food Chem.2015 Apr 1;172:885-92. doi: 10.1016/j.foodchem.2014.09.126. Epub 2014 Sep 28.
• Plant infusions are consumed due to their beneficial effects on health, which is attributed to their bioactive compounds content. However, these compounds are susceptible to degradation during processing and storage. The objective of this research was to evaluate the effect of stevia and citric acid
• PMID 25442634

• Antidiabetic Medications and Polypharmacy.

• Peron EP1, Ogbonna KC2, Donohoe KL3.
• Clinics in geriatric medicine.Clin Geriatr Med.2015 Feb;31(1):17-27. doi: 10.1016/j.cger.2014.08.017. Epub 2014 Oct 16.
• Polypharmacy, or the use of multiple medications, is a serious concern for providers who care for older adults, as polypharmacy is associated with medication nonadherence, drug-drug interactions, drug-disease interactions, and adverse drug events. Multiple medications, high chronic disease burden, a
• PMID 25453298

• Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.

• Zi FM1, He JS1, Li Y1, Wu C1, Yang L1, Yang Y1, Wang LJ1, He DH1, Zhao Y1, Wu WJ1, Zheng GF1, Han XY1, Huang H1, Yi Q2, Cai Z3.
• Cancer letters.Cancer Lett.2015 Jan 28;356(2 Pt B):443-53. doi: 10.1016/j.canlet.2014.09.050. Epub 2014 Oct 8.
• Epidemiologic studies and meta-analyses have suggested that patients with type 2 diabetes mellitus (T2DM) have a higher incidence of malignancies, including myeloma. Metformin is a widely prescribed antidiabetic drug. Recently, researchers have shown that metformin has direct anticancer activity aga
• PMID 25305450

Japanese Journal

• 糖尿病診療ガイドラインに基づく薬物選択のアルゴリズム (特集 糖尿病治療薬update : 適正な血糖管理を目指して)

• 岩本 安彦
• 日本臨床 73(3), 382-389, 2015-03
• NAID 40020366916

• 糖尿病治療薬の変遷と今後の展望 (特集 糖尿病治療薬update : 適正な血糖管理を目指して)

• 川浪 大治,宇都宮 一典
• 日本臨床 73(3), 375-381, 2015-03
• NAID 40020366899

• Simultaneous Analysis of Oral Antidiabetic Drug by LC-MS/MS

• KAI Shigemi,ISHIKAWA Ken,ITO Hajime [他]
• Chromatography : Journal of separation and detection sciences = クロマトグラフィー : 分離・検出科学 36(1), 19-24, 2015
• NAID 40020465814

Related Links

• antidiabetic - definition of antidiabetic in the Medical dictionary ...

antidiabetic /an·ti·di·a·bet·ic/ (-di″ah-bet´ik) 1. preventing or alleviating diabetes. 2. an agent that so acts. antidiabetic [-dī′əbet′ik] pertaining to an agent that prevents or relieves symptoms of diabetes. antidiabetic antidiabetic adjective ...

• Antidiabetic - World News

Diabetes Medications, Anti-Diabetic Drug ACTOS pharmacology Nursing Students (Pa, Pharmatube-Endocrine-8-Pancreatic Hormones & Antidiabetic drugs, New antidiabetic drugs: differentiation is the key, Diabetes Drugs Made ... ...

Related Pictures

---

★リンクテーブル★

リンク元	「糖尿病治療薬」「抗糖尿病薬」「抗糖尿病剤」「抗糖尿病」「抗糖尿病性」
拡張検索	「antidiabetic drug」「antidiabetic agent」
関連記事	「antidiabetics」

「糖尿病治療薬」

　　[★]

英

antidiabetic, antidiabetics, antidiabetic drug

関

薬理学、糖尿病

SPC. 347

　肥満度高　　　　　　　　ビグアナイド
　
　肥満度低　　　　　αGI　　　　　　SU剤
　　　　　　　血糖値低　　　中　　　　高

糖尿病治療薬と体重

DMR.110

	血中インスリン濃度	単剤使用での低血糖	体重
インスリン分泌刺激薬	↑	○	↑
ビグアニド系薬	→～↓	△	→～↓
αグルコシダーゼ阻害薬	→	××	→
インスリン抵抗性改善薬	→～↓	△	↑
インスリン	↑	○	↑

禁忌

• 妊婦に対しては経口糖尿病治療薬は禁忌。
• 腎不全に対してはスルホニル尿酸薬(遷延性の低血圧を来す危険あり)やビグアニド薬(乳酸アシドーシスを来す危険有り)は禁忌。

「抗糖尿病薬」

　　[★]

英

antidiabetic、antidiabetic agent、antidiabetic drug

関

血糖降下剤、血糖降下薬、抗糖尿病性、抗糖尿病剤、抗糖尿病

「抗糖尿病剤」

　　[★]

英

antidiabetic drug、antidiabetic

関

抗糖尿病性、抗糖尿病薬、抗糖尿病

「抗糖尿病」

　　[★]

英

antidiabetic

関

抗糖尿病性、抗糖尿病薬、抗糖尿病剤

「抗糖尿病性」

　　[★]

英

antidiabetic

関

抗糖尿病薬、抗糖尿病剤、抗糖尿病

「antidiabetic drug」

　　[★]

• 抗糖尿病薬、抗糖尿病剤

関

antidiabetic、antidiabetic agent、antidiabetics、hypoglycemic agent、hypoglycemic drug、hypoglycemics

「antidiabetic agent」

　　[★]

• 抗糖尿病薬

関

antidiabetic、antidiabetic drug、antidiabetics、hypoglycemic agent、hypoglycemic drug、hypoglycemics

「antidiabetics」

　　[★]

抗糖尿病薬、抗糖尿病剤

関

antidiabetic、antidiabetic agent、antidiabetic drug、hypoglycemic agent、hypoglycemic drug、hypoglycemics